Do some glucagon-like-peptide-1 receptor agonists (GLP-1 RA) reduce macrovascular complications of type 2 diabetes mellitus?: A commentary on the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial

Current Vascular Pharmacology

Volumn 14, Issue 5, 2016, Pages 469-473

  Athyros, Vasilios G ^a   Katsiki, Niki ^a   Tentolouris, Nikolaos ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cardiovascular disease; Dipeptidyl peptidase 4 inhibitors; Glucagon like peptide 1 receptor agonists; Heart failure; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE;

AGONISTS; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DIABETIC COMPLICATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PROCEDURES; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; TREATMENT OUTCOME;

EID: 85019608363     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161114666160909161537     Document Type: Editorial

References (37)

1. Sturm G, Lamina C, Zitt E, et al. Association of HbA1c values with mortality and cardiovascular events in diabetic dialysis patients. The INVOR study and review of the literature. PLoS One 2011; 6: e20093.
2. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012; 35(suppl 1): S11-S63.
3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-65.
4. Dormandy JA, Charbonnel B, Eckland DJ, et al. Proactive investigators. Secondary prevention of macro vascular events in patients with type 2 diabetes in the PROactive Study (Prospective pioglit Azone Clinical Trial In macro Vascular Events): a randomized controlled trial. Lancet 2005; 366: 1279-89.
5. Gerstein HC, Miller ME, Byington RP, et al. Action to control cardiovascular risk in diabetes study group. N Engl J Med 2008; 358: 2545-59.
6. Sardar P, Udell JA, Chatterjee S, et al. Effect of intensive versus standard blood glucose control in patients with type 2 diabetes mellitus in different regions of the world: systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2015; e001577.
7. Athyros VG, Katsiki N, Karagiannis A. Can glucagon like peptide 1 (GLP1) agonists or sodium-glucose co-transporter 2 (SGLT2) inhibitors ameliorate non-alcoholic steatohepatitis in people with or without diabetes? Cur Vasc Pharmacol 2016 in press.
8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
9. Green JB, Bethel MA, Armstrong PW, et al. TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373: 232-42.
10. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-28.
11. Scirica BM, Bhatt DL, Braunwald E, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-26.
12. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015; 385: 2067-76.
13. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012; 11: 3.
14. Paul SK, Klein K, Maggs D, Best JH. The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovasc Diabetol 2015; 14: 10.
15. Anyanwagu U, Mamza J, Mehta R, Donnelly R, Idris I. Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes. Heart 2016 May 23. pii: heartjnl-2015-309164.
16. Kang YM, Jung CH. Cardiovascular effects of glucagon-like peptide-1 receptor agonists. Endocrinol Metab (Seoul) 2016 Apr 25. [Epub ahead of print].
17. Katsiki N, Christou GA, Kiortsis DN. Liraglutide and cardiometabolic effects: More than just another antiobesity drug? Curr Vasc Pharmacol 2016; 14: 76-9.
18. Christou GA, Katsiki N, Kiortsis DN. The current role of liraglutide in the pharmacotherapy of obesity. Curr Vasc Pharmacol 2015 Jun 15. [Epub ahead of print].
19. Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011; 9: 531-2.
20. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011; 9: 258-70.
21. Pfeffer MA, Claggett B, Diaz R, et al. ELIXA investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373: 2247-57.
22. Fisher M, Petrie MC, Ambery PD, Donaldson J, Ye J, McMurray JJ. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol 2015; 3: 697-703.
23. Heppner KM, Marks S, Holland J, et al. Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice. Diabetologia 2015; 58: 2124-32.
24. Karras S, Goulis DG, Mintziori G, Katsiki N, Tzotzas T. The effects of incretins on energy homeostasis: physiology and implications for the treatment of type 2 diabetes mellitus and obesity. Curr Vasc Pharmacol 2012; 10: 781-91.
25. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; In Press. DOI: 10. 1056/NEJMoa1603827.
26. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016; 374: 1321-31.
27. Giannoglou GD, Chatzizisis YS, Zamboulis C, Parcharidis GE, Mikhailidis DP, Louridas GE. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol 2008; 126: 302-12.
28. Katsiki N, Athyros VG, Mikhailidis DP. Cardiovascular effects of sodium-glucose cotransporter 2 inhibitors: multiple actions. Curr Med Res Opin 2016 Jun 16:1-6.
29. Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes 2015; 6: 1246-58.
30. Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009; 297: 127-36.
31. Wysham CH, MacConell LA, Maggs DG, Zhou M, Griffin PS, Trautmann ME. Five-year efficacy and safety data of exenatide once weekly: longterm results from the DURATION-1 randomized clinical trial. Mayo Clin Proc 2015; 90: 356-65.
32. Holman RR, Bethel MA, George J, et al. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. Am Heart J 2016; 174: 103-10.
33. Wanner C, Inzucchi SE, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016.
34. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent? Curr Vasc Pharmacol 2012; 10: 374-7.
35. Munir KM, Davis SN. Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes. Clin Pharmacol 2016; 8: 19-34.
36. Boonman-de Winter LJ, Cramer MJ, Hoes AW, Rutten FH. Uncovering heart failure with preserved ejection fraction in patients with type 2 diabetes in primary care: time for a change. Neth Heart J 2016; 24: 237-43.
37. Athyros VG, Papageorgiou AA, Symeonidis AN, et al; GREACE Study Collaborative Group. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology 2003; 54: 679-90.